Good Samaritan Hospital

Az itteni vizsgálatok

Miről szól a helyszín 19 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák10 vizsgálat
• Tripla negatív emlőrák3 vizsgálat
• Vastagbélrák3 vizsgálat
• Gyermekkori daganatok2 vizsgálat
• Hólyagrák2 vizsgálat
• Máj- és epeúti rák2 vizsgálat
• Fej-nyaki daganatok1 vizsgálat
• Gyomor- és nyelőcsőrák1 vizsgálat
• Hasnyálmirigyrák1 vizsgálat
• Méhnyakrák1 vizsgálat
• Méhtestrák1 vizsgálat
• Melanóma1 vizsgálat
• és még 5

Fázis

• 3. fázis12 vizsgálat
• 2. fázis4 vizsgálat
• 2/3. fázis1 vizsgálat

Állapot

• Fut, nem toboroz15 vizsgálat
• Lezárult2 vizsgálat
• Toboroz2 vizsgálat

Fő szponzor

• National Cancer Institute (NCI)11 vizsgálat
• Alliance for Clinical Trials in Oncology2 vizsgálat
• ECOG-ACRIN Cancer Research Group2 vizsgálat
• NRG Oncology2 vizsgálat
• SWOG Cancer Research Network2 vizsgálat

Futó vizsgálatok

• Fut, nem toboroz

  Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

  NCT04533451· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás

• Fut, nem toboroz

  Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

  NCT04496739· SWOG Cancer Research Network· Forrás

• Toboroz

  Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  NCT04267848· 3. fázis· National Cancer Institute (NCI)· Forrás

  Contact: John Strother (principal investigator)

• Fut, nem toboroz

  Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

  NCT04092283· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás

• Toboroz

  Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  NCT03191149· 2. fázis· National Cancer Institute (NCI)· Forrás

  Contact: John Strother (principal investigator)

• Fut, nem toboroz

  Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

  NCT03244384· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT03137771· 2. fázis· NRG Oncology· Forrás

• Fut, nem toboroz

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás

• Fut, nem toboroz

  Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060· 2. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· 3. fázis· NRG Oncology· Forrás

• Fut, nem toboroz

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás

• Fut, nem toboroz

  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282· 3. fázis· National Cancer Institute (NCI)· Forrás

• Fut, nem toboroz

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· National Cancer Institute (NCI)· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák2 toboroz

Lezárt vizsgálatok

• Lezárult

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· 3. fázis· SWOG Cancer Research Network· Forrás

• Lezárult

  Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554· 2/3. fázis· National Cancer Institute (NCI)· Forrás